New drug duo tested in fight against rare, aggressive eye cancer
NCT ID NCT04552223
Summary
This study tested whether combining two immunotherapy drugs, nivolumab and relatlimab, could shrink tumors in people with metastatic uveal melanoma, a rare and aggressive cancer that starts in the eye. The trial involved 27 patients who had not received similar treatments before. Participants received the drug combination by IV every four weeks for up to two years, and researchers measured how many people's tumors responded.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC UVEAL MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Miami Sylvester Comprehensive Cancer Center
Miami, Florida, 33136, United States
Conditions
Explore the condition pages connected to this study.